MARSHALL UNIVERSITY

AI Accelerates Clinical Trial Recruitment, Reducing Enrollment Times and Costs

8 months ago

• Artificial intelligence (AI) is transforming clinical trial patient recruitment, particularly for rare and ultrarare diseases, by streamlining the matching of patients to trials. • AI technologies, including machine learning and natural language processing, harmonize data from global registries and natural history studies to identify eligible patients. • Studies show AI can reduce patient enrollment times by 10% to 15% and increase the accurate identification of eligible patients by 24% to 50% in cancer trials. • AI-driven systems automate patient matching, expedite recruitment, lower costs, and improve patient access to potentially life-saving treatments.

Lofexidine Trial Launched for Neonatal Opioid Withdrawal Syndrome

9 months ago

• Marshall University is conducting a clinical trial to assess oral lofexidine, a non-opioid medication, for treating Neonatal Opioid Withdrawal Syndrome (NOWS). • The Phase 2 trial aims to evaluate the safety and pharmacokinetics of lofexidine in newborns exposed to opioids prenatally. • Unlike opioid-based treatments, lofexidine does not produce euphoria or addiction potential, offering a potentially safer alternative. • The study will monitor NOWS symptoms using the Modified Finnegan Neonatal Abstinence Scoring Tool (mFNAST) and assess treatment duration.